We’ve recently updated our valuation analysis.

Oncimmune Holdings Valuation

Is ONC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONC?

Other financial metrics that can be useful for relative valuation.

ONC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.1x
Enterprise Value/EBITDA-5.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ONC's PS Ratio compare to its peers?

The above table shows the PS ratio for ONC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average30.6x
DDDD 4D pharma
51.3x66.8%UK£30.0m
OPTI OptiBiotix Health
13.7xn/aUK£17.2m
TRX Tissue Regenix Group
2.3x21.0%UK£41.8m
AREC Arecor Therapeutics
55x79.6%UK£76.5m
ONC Oncimmune Holdings
8xn/aUK£30.9m

Price-To-Sales vs Peers: ONC is good value based on its Price-To-Sales Ratio (8x) compared to the peer average (30.6x).


Price to Earnings Ratio vs Industry

How does ONC's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.3%
n/an/an/a

Price-To-Sales vs Industry: ONC is good value based on its Price-To-Sales Ratio (8x) compared to the European Biotechs industry average (11.4x)


Price to Sales Ratio vs Fair Ratio

What is ONC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ONC's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ONC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of ONC's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Oncimmune Holdings regulatory filings.
  • Potentially undervalued companies in the Pharmaceuticals & Biotech industry.